title: [Clinical efficiency of candesartan in patients with renoparenchymal hypertension in dependence on genotype of angeotensin II receptors of I type].
abstract: The authors present obtained data on the frequency of genotypes and A and C alleles of polymorphous gene related to Angiotension II first type receptor in patients of Poltava region. These patients were with chronic pyelonephritis and arterial hypertension. Therapeutic efficacy of candesartan treatment of the patients and at the same time their genotypes were considered. Obtained data evidence that AC genotype is more often found among patients with reniparenchymal hypertension, genotype CC is less found among these patients and genotype AA occupies an intermediate place (in 1,7 times less found than among healthy individuals and in 2,2 times more often than among patients with essential hypertension). Candesartan used in monotherapy has a high clinical efficiency in the treatment of patients with AC genotype. Patients with genotype AA and severe course of their disease have to be in a complex treatment or prescribed is applied candesartan in high dosage.
authors.forename: I P
authors.initials: IP
authors.lastname: Kaĭdashev
authors.forename: M S
authors.initials: MS
authors.lastname: Rasin
authors.forename: I A
authors.initials: IA
authors.lastname: Nerukh
authors.forename: O A
authors.initials: OA
authors.lastname: Borzykh
authors.forename: O A
authors.initials: OA
authors.lastname: Shlykova
mesh_terms: D000328:Adult; D047228:Angiotensin II Type 1 Receptor Blockers / Q000008:administration & dosage / Q000627:therapeutic use*; D001562:Benzimidazoles / Q000008:administration & dosage / Q000627:therapeutic use*; D001713:Biphenyl Compounds; D001794:Blood Pressure / Q000187:drug effects / Q000235:genetics; D004247:DNA / Q000032:analysis; D004305:Dose-Response Relationship, Drug; D005787:Gene Frequency; D005838:Genotype; D006801:Humans; D006977:Hypertension, Renal / Q000188:drug therapy* / Q000235:genetics; D008297:Male; D008875:Middle Aged; D011110:Polymorphism, Genetic; D044140:Receptor, Angiotensin, Type 1 / Q000235:genetics*; D013777:Tetrazoles / Q000008:administration & dosage / Q000627:therapeutic use*; D016896:Treatment Outcome
chemical_list: D047228:Angiotensin II Type 1 Receptor Blockers; D001562:Benzimidazoles; D001713:Biphenyl Compounds; D044140:Receptor, Angiotensin, Type 1; D013777:Tetrazoles; D004247:DNA; C081643:candesartan